β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease

Ryu,Young-Kyoung; Park,Hye-Yeon; Go,Jun; Lee,In-Bok; Choi,Young-Keun; Lee,Chul-Ho; Kim,Kyoung-Shim

doi:10.3892/mmr.2021.11856

β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease

Authors:
- Young-Kyoung Ryu
- Hye-Yeon Park
- Jun Go
- In-Bok Lee
- Young-Keun Choi
- Chul-Ho Lee
- Kyoung-Shim Kim
View Affiliations

Affiliations: Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea
Published online on: January 20, 2021 https://doi.org/10.3892/mmr.2021.11856
Article Number: 217
Copyright: © Ryu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The dopamine precursor 3,4‑dihydroxyphenyl‑ l‑alanine (L‑DOPA) is the most widely used symptomatic treatment for Parkinson's disease (PD); however, its prolonged use is associated with L‑DOPA‑induced dyskinesia in more than half of patients after 10 years of treatment. The present study investigated whether co‑treatment with β‑Lapachone, a natural compound, and L‑DOPA has protective effects in a 6‑hydroxydopamine (6‑OHDA)‑induced mouse model of PD. Unilateral 6‑OHDA‑lesioned mice were treated with vehicle or β‑Lapachone (10 mg/kg/day) and L‑DOPA for 11 days. Abnormal involuntary movements (AIMs) were scored on days 5 and 10. β‑Lapachone (10 mg/kg) co‑treatment with L‑DOPA decreased the AIMs score on both days 5 and 10. β‑Lapachone was demonstrated to have a beneficial effect on the axial and limb AIMs scores on day 10. There was no significant suppression in dopamine D1 receptor‑related and ERK1/2 signaling in the DA‑denervated striatum by β‑Lapachone‑cotreatment with L‑DOPA. Notably, β‑Lapachone‑cotreatment with L‑DOPA increased phosphorylation at the Ser9 site of glycogen synthase kinase 3β (GSK‑3β), indicating suppression of GSK‑3β activity in both the unlesioned and 6‑OHDA‑lesioned striata. In addition, astrocyte activation was markedly suppressed by β‑Lapachone‑cotreatment with L‑DOPA in the striatum and substantia nigra of the unilateral 6‑OHDA model. These findings suggest that β‑Lapachone cotreatment with L‑DOPA therapy may have therapeutic potential for the suppression or management of the development of L‑DOPA‑induced dyskinesia in patients with PD.

View Figures

View References

1	Moon DO, Choi YH, Kim ND, Park YM and Kim GY: Anti-inflammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol. 7:506–514. 2007. View Article : Google Scholar : PubMed/NCBI
2	Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA and Nelson LM: Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol. 157:1015–1022. 2003. View Article : Google Scholar : PubMed/NCBI
3	Cotzias GC: L-Dopa for Parkinsonism. N Engl J Med. 278:6301968. View Article : Google Scholar : PubMed/NCBI
4	Tran TN, Vo TNN, Frei K and Truong DD: Levodopa-induced dyskinesia: Clinical features, incidence, and risk factors. J Neural Transm (Vienna). 125:1109–1117. 2018. View Article : Google Scholar : PubMed/NCBI
5	Jenner P: Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 9:665–677. 2008. View Article : Google Scholar : PubMed/NCBI
6	Santini E, Heiman M, Greengard P, Valjent E and Fisone G: Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal. 2:ra362009. View Article : Google Scholar : PubMed/NCBI
7	Santini E, Alcacer C, Cacciatore S, Heiman M, Hervé D, Greengard P, Girault JA, Valjent E and Fisone G: L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem. 108:621–633. 2009. View Article : Google Scholar : PubMed/NCBI
8	Park HY, Kang YM, Kang Y, Park TS, Ryu YK, Hwang JH, Kim YH, Chung BH, Nam KH, Kim MR, et al: Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease. J Neurosci. 34:11744–11753. 2014. View Article : Google Scholar : PubMed/NCBI
9	Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, et al: M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia. Neuron. 88:762–773. 2015. View Article : Google Scholar : PubMed/NCBI
10	Carta AR, Mulas G, Bortolanza M, Duarte T, Pillai E, Fisone G, Vozari RR and Del-Bel E: l-DOPA-induced dyskinesia and neuroinflammation: Do microglia and astrocytes play a role? Eur J Neurosci. 45:73–91. 2017. View Article : Google Scholar : PubMed/NCBI
11	McGeer PL, Itagaki S, Boyes BE and McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1285–1291. 1988. View Article : Google Scholar : PubMed/NCBI
12	Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D, Vila M, Jackson-Lewis V and Przedborski S: Pathogenic role of glial cells in Parkinson's disease. Mov Disord. 18:121–129. 2003. View Article : Google Scholar : PubMed/NCBI
13	Bortolanza M, Cavalcanti-Kiwiatkoski R, Padovan-Neto FE, da-Silva CA, Mitkovski M, Raisman-Vozari R and Del-Bel E: Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. Neurobiol Dis. 73:377–387. 2015. View Article : Google Scholar : PubMed/NCBI
14	Schaffner-Sabba K, Schmidt-Ruppin KH, Wehrli W, Schuerch AR and Wasley JW: beta-Lapachone: Synthesis of derivatives and activities in tumor models. J Med Chem. 27:990–994. 1984. View Article : Google Scholar : PubMed/NCBI
15	Gomez Castellanos JR, Prieto JM and Heinrich M: Red lapacho (Tabebuia impetiginosa)-a global ethnopharmacological commodity? J Ethnopharmacol. 121:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
16	Hussain H and Green IR: Lapachol and lapachone analogs: A journey of two decades of patent research (1997–2016). Expert Opin Ther Pat. 27:1111–1121. 2017. View Article : Google Scholar : PubMed/NCBI
17	Xu J, Wagoner G, Douglas JC and Drew PD: β-Lapachone ameliorization of experimental autoimmune encephalomyelitis. J Neuroimmunol. 254:46–54. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kim KH, Le TH, Oh HK, Heo B, Moon J, Shin S and Jeong SH: Protective microencapsulation of β-lapachone using porous glass membrane technique based on experimental optimisation. J Microencapsul. 34:545–559. 2017. View Article : Google Scholar : PubMed/NCBI
19	Lee M, Ban JJ, Chung JY, Im W and Kim M: Amelioration of Huntington's disease phenotypes by Beta-Lapachone is associated with increases in Sirt1 expression, CREB phosphorylation and PGC-1α deacetylation. PLoS One. 13:e01959682018. View Article : Google Scholar : PubMed/NCBI
20	Park JS, Leem YH, Park JE, Kim DY and Kim HS: Neuroprotective effect of β-lapachone in MPTP-induced parkinson's disease mouse model: Involvement of astroglial p-AMPK/Nrf2/HO-1 signaling pathways. Biomol Ther (Seoul). 27:178–184. 2019. View Article : Google Scholar : PubMed/NCBI
21	Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D and Boothman DA: NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem. 275:5416–5424. 2000. View Article : Google Scholar : PubMed/NCBI
22	Beaver SK, Mesa-Torres N, Pey AL and Timson DJ: NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms. Biochim Biophys Acta Proteins Proteom. 1867:663–676. 2019. View Article : Google Scholar : PubMed/NCBI
23	Go J, Ryu YK, Park HY, Choi DH, Choi YK, Hwang DY, Lee CH and Kim KS: NQO1 regulates pharmaco-behavioral effects of d-amphetamine in striatal dopaminergic system in mice. Neuropharmacology. 170:1080392020. View Article : Google Scholar : PubMed/NCBI
24	Lee EJ, Ko HM, Jeong YH, Park EM and Kim HS: β-Lapachone suppresses neuroinflammation by modulating the expression of cytokines and matrix metalloproteinases in activated microglia. J Neuroinflammation. 12:1332015. View Article : Google Scholar : PubMed/NCBI
25	Park JS, Lee YY, Kim J, Seo H and Kim HS: β-Lapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes. Free Radic Biol Med. 97:168–178. 2016. View Article : Google Scholar : PubMed/NCBI
26	Ryu YK, Park HY, Go J, Choi DH, Kim YH, Hwang JH, Noh JR, Lee TG, Lee CH and Kim KS: Metformin inhibits the development of L-DOPA-induced dyskinesia in a murine model of Parkinson's disease. Mol Neurobiol. 55:5715–5726. 2018. View Article : Google Scholar : PubMed/NCBI
27	Ryu YK, Go J, Park HY, Choi YK, Seo YJ, Choi JH, Rhee M, Lee TG, Lee CH and Kim KS: Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging. Neuropharmacology. 175:1081732020. View Article : Google Scholar : PubMed/NCBI
28	Faull RL and Laverty R: Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp Neurol. 23:332–340. 1969. View Article : Google Scholar : PubMed/NCBI
29	Jeon BS, Jackson-Lewis V and Burke RE: 6-Hydroxydopamine lesion of the rat substantia nigra: Time course and morphology of cell death. Neurodegeneration. 4:131–137. 1995. View Article : Google Scholar : PubMed/NCBI
30	Xie CL, Lin JY, Wang MH, Zhang Y, Zhang SF, Wang XJ and Liu ZG: Inhibition of glycogen synthase kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci Rep. 6:235272016. View Article : Google Scholar : PubMed/NCBI
31	Georgievska B, Sandin J, Doherty J, Mörtberg A, Neelissen J, Andersson A, Gruber S, Nilsson Y, Schött P, Arvidsson PI, et al: AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J Neurochem. 125:446–456. 2013. View Article : Google Scholar : PubMed/NCBI
32	Frame S and Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 359:1–16. 2001. View Article : Google Scholar : PubMed/NCBI
33	Pavon N, Martin AB, Mendialdua A and Moratalla R: ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry. 59:64–74. 2006. View Article : Google Scholar : PubMed/NCBI
34	Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Hervé D, Greengard P and Fisone G: Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 27:6995–7005. 2007. View Article : Google Scholar : PubMed/NCBI
35	Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT and Collingridge GL: The role of GSK-3 in synaptic plasticity. Br J Pharmacol. 153 (Suppl 1):S428–S437. 2008. View Article : Google Scholar : PubMed/NCBI
36	Lucas FR, Goold RG, Gordon-Weeks PR and Salinas PC: Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci. 111:1351–1361. 1998.PubMed/NCBI
37	Rui Y, Myers KR, Yu K, Wise A, De Blas AL, Hartzell HC and Zheng JQ: Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3β. Nat Commun. 4:26282013. View Article : Google Scholar : PubMed/NCBI
38	Golpich M, Amini E, Hemmati F, Ibrahim NM, Rahmani B, Mohamed Z, Raymond AA, Dargahi L, Ghasemi R and Ahmadiani A: Glycogen synthase kinase-3 beta (GSK-3 β) signaling: Implications for Parkinson's disease. Pharmacol Res. 97:16–26. 2015. View Article : Google Scholar : PubMed/NCBI
39	Mulas G, Espa E, Fenu S, Spiga S, Cossu G, Pillai E, Carboni E, Simbula G, Jadžić D, Angius F, et al: Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease. Exp Neurol. 286:83–92. 2016. View Article : Google Scholar : PubMed/NCBI
40	Barnum CJ, Eskow KL, Dupre K, Blandino P Jr, Deak T and Bishop C: Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: Role for interleukin-1beta. Neuroscience. 156:30–41. 2008. View Article : Google Scholar : PubMed/NCBI